Visual AcuityNCT05747417
Prismatic Correction for Improving Near Visual Acuity in Patients With Maculopathy
A study testing prismatic glasses in people with Visual Acuity, run by Al-Shifa Trust Eye Hospital at 1 site in Pakistan.
Trial summary
patients with maculopathy reported in low vision clinic are tested for prismatic glasses for near vision. The pre and post visual acuity was recorded. Read more about this study
- Who is it for?
- Ages 40 years and olderHealthy volunteers can take part
- Conditions the study is for
- Visual Acuity
- What is being tested?
- prismatic glasses
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 100 participants
- Where
- 1 sitePakistan
- Study dates
- 1 Jun 2022to 31 Dec 2022
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Diagnosed patients of maculopathy refer to low vision clinic
- Patients with both genders
- VA from LogMAR 1.0 to LogMAR 0.3
Who cannot join
- Maculopathy patients with other ocular disease
- VA worsen the LogMAR 1.0
- Patients with mental illness and other physical lmitations
Trial locations and contacts
1 site in 1 country.
Pakistan1 site
Al Shifa Trust Eye Hospital Rawalpindi
Rawalpindi, Punjab Province
About this study
patients with maculopathy reported in low vision clinic are tested for prismatic glasses for near vision. The pre and post visual acuity was recorded.
Read the detailed description
Diagnosed patient of maculopathy who was visited in low vision clinic are divided in two groups , one is control group (prescribed simple near vision glasses) and other is interventional group(prescribed prismatic glasses). Both groups were follow up after one month to check the improvement in near visual acuity
- Conditions
- Visual Acuity
- Being tested
- prismatic glasses
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
prismatic glassesOther
prism glasses ranging from 4-10 prism diopters
| Study group | Role | What they receive |
|---|---|---|
| prism glasses | Experimental | prisms glasses are advised with ranging of 4prism diopters to 10 prism diopters Receives: Other: prismatic glasses |
| presbyopic glasses | No intervention | simple presbyopia glasses according to age are advised |
What is being measured
The primary outcome is the main question the study is designed to answer.
Prismatic Correction for Improving Near Visual Acuity in Patients with Maculopathy
A Per forma/questionnaire is used to document Near visual Acuity with the help of light house Chart to see improvement in visual acuity
Measured: 7 -8 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Feb 2023
- Study start1 Jun 2022
- Primary completion31 Dec 2022
- Study completion31 Dec 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Visual AcuityStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Investigator
- Enrolment
- 100 participants (actual)
Sponsor and investigators
- Lead sponsor
- Al-Shifa Trust Eye Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Mehreen Tanveer, Al-Shifa Trust Eye Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05747417
- Sponsor's protocol ID
- AlShifaTrust Eye
- Status last verified
- Feb 2023
- First submitted
- 25 Jan 2023
- Last updated
- 28 Feb 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 28 Feb 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prismatic Correction for Improving Near Visual Acuity in Patients With Maculopathy
- ClinicalTrials.gov ID
- NCT05747417
- Acronym / sponsor ID
- AlShifaTrust Eye
- Conditions
- Visual Acuity
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 100 participants (actual)
- Lead sponsor
- Al-Shifa Trust Eye HospitalUniversity, hospital or other
- Study start
- 1 Jun 2022 (actual)
- Primary completion
- 31 Dec 2022 (actual)
- Study completion
- 31 Dec 2022 (actual)
- First posted
- 28 Feb 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
patients with maculopathy reported in low vision clinic are tested for prismatic glasses for near vision. The pre and post visual acuity was recorded.
Detailed description
Diagnosed patient of maculopathy who was visited in low vision clinic are divided in two groups , one is control group (prescribed simple near vision glasses) and other is interventional group(prescribed prismatic glasses). Both groups were follow up after one month to check the improvement in near visual acuity
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| prism glasses | Experimental | Other: prismatic glassesprisms glasses are advised with ranging of 4prism diopters to 10 prism diopters |
| presbyopic glasses | No intervention | –simple presbyopia glasses according to age are advised |
Who may qualify
- Ages
- 40 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Diagnosed patients of maculopathy refer to low vision clinic
- Patients with both genders
- VA from LogMAR 1.0 to LogMAR 0.3
Key exclusion criteria (3 listed)
- Maculopathy patients with other ocular disease
- VA worsen the LogMAR 1.0
- Patients with mental illness and other physical lmitations
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| prismatic glassesprism glasses ranging from 4-10 prism diopters | Other | prism glasses |
Primary outcome
Prismatic Correction for Improving Near Visual Acuity in Patients with Maculopathy
Time frame: 7 -8 months
A Per forma/questionnaire is used to document Near visual Acuity with the help of light house Chart to see improvement in visual acuity
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Feb 2023.
- Individual participant dataSharing planned: No
Related trials for Visual Acuity
Active, not recruiting
Evaluation of Approved Contact Lenses (CR-6657)
Visual Acuity
Recruiting
Comparison of ACUVUE® OASYS MAX 1-Day Multifocal and DAILIES® AquaComfort Plus® Multifocal
Visual Acuity
RecruitingPhase 3
Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)
Neovascular Age-related Macular Degeneration
Active, not recruitingPhase 2
Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration [LUNA]
Neovascular Age-related Macular Degeneration
RecruitingPhase 3
Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 mg) Intravitreal Implants vs Observation for Prevention of VA Loss Due to Radiation Retinopathy
Radiation Retinopathy, Visual Impairment
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing prismatic glasses in people with Visual Acuity, run by Al-Shifa Trust Eye Hospital at 1 site in Pakistan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 28 Feb 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Pakistan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Prismatic Correction for Improving Near Visual Acuity in Patients with Maculopathy (time frame: 7 -8 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Feb 2023.